In the final part of his conversation with Pharmaceutical Executive, Aravo CCO Dave Rusher discusses the various regulatory updates around the world in the pharma and AI space.
Dave Rusher
Advertisement
Dave Rusher is CCO at Aravo.
Articles by Dave Rusher
Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.
Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Foundayo Under National Priority Voucher Program
2
Trump Administration’s Leadership Carousel Across Key Agencies
3
The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target
4
More Than Just Pricing: MFN’s Impact on Pharma: Q&A with Lindsay Bealor Greenleaf
5